Part of drug trial for patients with atrial fibrillation discontinued
6th Sep 2005, 22:07 GMT
Study treatments for the ACTIVE W trial of the ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) program have been discontinued due to a significant difference in efficacy, in favour of the standard oral anticoagulation (OAC) over antiplatelet therapy (clopidogrel plus aspirin).
Latest news from EurekAlert! - Medicine and Health:
- Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years
- Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data
- UCSD computer scientist wins Young Investigator Award, research on snake venom proteins highlighted
- Why do insects like to eat some plants more than others?
- Opposites do not attract
- Wild gorillas carriers of an SIV virus close to the AIDS virus
- New data show ACTOS (pioglitazone HCl) halted progression of atherosclerosis as indicated by CIMT
- Pourquié lab identifies genes involved in formation of vertebral precursors
- Artificial cornea offers better results for infants, some blind patients
- Healthier kids just the click of a remote away